Mythic Therapeutics to Present KisMET-01 Phase 1 Data at ASCO Annual Meeting

Mythic Therapeutics, a biotech firm based in Waltham, Mass., is advancing in its efforts to develop innovative treatments for various cancers. The company, known for focusing on next-generation antibody-drug conjugate (ADC) therapies, has recently announced promising results from a Phase 1 clinical trial. This trial, named KisMET-01, is evaluating the experimental ADC MYTX-011 in patients with previously treated, locally advanced, or metastatic non-small cell lung cancer (NSCLC). The early findings will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Gilles Gallant, BPharm, Ph.D., FOPQ, and Chief Development Officer at Mythic Therapeutics, expressed enthusiasm about the initial clinical data. Gallant highlighted that the preliminary dose escalation results from the ongoing KisMET-01 trial represent a significant milestone for MYTX-011. He emphasized the importance of sharing these findings with the broader scientific community at ASCO.

The presentation details are as follows:
- Title: MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study.
- Presenter: Dr. Melissa Johnson, Director, Lung Cancer Research at the Sarah Cannon Research Institute
- Session Title: Lung Cancer—Non-Small Cell Metastatic
- Session Date and Time: Monday, June 3, from 1:30 to 4:30 PM CDT
- Location: Hall A | On Demand
- Poster Board Number: 422
- Published Abstract Number: 8558

MYTX-011 is a cutting-edge, investigational cMET-targeting ADC that utilizes Mythic's proprietary FateControl™ technology. This technology is designed to optimize the delivery of anti-cancer agents directly to tumor cells while minimizing the impact on healthy cells. Unlike traditional linker-payload technologies, FateControl™ aims to improve the efficacy of ADCs by actively managing their behavior within cells. This innovative approach has the potential to enhance treatment outcomes across various molecular targets and patient profiles.

The KisMET-01 clinical trial is a first-in-human, open-label, multi-center study that includes both dose escalation and dose expansion phases. It is currently enrolling patients with locally advanced, recurrent, or metastatic NSCLC (NCT05652868). The primary objective is to assess the safety and preliminary efficacy of MYTX-011 in this patient population.

Mythic Therapeutics is a company dedicated to developing a pipeline of ADCs with an unparalleled therapeutic index and effectiveness. The firm's FateControl™ technology aims to enhance ADC uptake in targeted tissues by controlling their intracellular behavior. This advancement could significantly broaden the range of diseases and patient profiles that can be treated with Mythic's ADCs.

The company is backed by prominent investors such as Venrock, Viking Global Investors, and First Round Capital. Mythic's innovative approach and commitment to improving cancer treatment continue to drive its research and development efforts.